BRPI0411650A - variante polipeptìdica do fator vii (fvii) ou do fator viia (fviia), sequencia de nucleotìdeos , vetor de expressão, célula hospedeira, composição, uso de uma variante, e, método para tratar de um mamìfero tendo uma doença ou um distúrbio em que a formação de coágulo seja desejável - Google Patents

variante polipeptìdica do fator vii (fvii) ou do fator viia (fviia), sequencia de nucleotìdeos , vetor de expressão, célula hospedeira, composição, uso de uma variante, e, método para tratar de um mamìfero tendo uma doença ou um distúrbio em que a formação de coágulo seja desejável

Info

Publication number
BRPI0411650A
BRPI0411650A BRPI0411650-0A BRPI0411650A BRPI0411650A BR PI0411650 A BRPI0411650 A BR PI0411650A BR PI0411650 A BRPI0411650 A BR PI0411650A BR PI0411650 A BRPI0411650 A BR PI0411650A
Authority
BR
Brazil
Prior art keywords
variant
fviia
fvii
mammal
disorder
Prior art date
Application number
BRPI0411650-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Jesper Mortensen Haaning
Kim Vilbour Andersen
Claus Bornaes
Original Assignee
Maxygen Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxygen Holdings Ltd filed Critical Maxygen Holdings Ltd
Publication of BRPI0411650A publication Critical patent/BRPI0411650A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
BRPI0411650-0A 2003-06-19 2004-06-18 variante polipeptìdica do fator vii (fvii) ou do fator viia (fviia), sequencia de nucleotìdeos , vetor de expressão, célula hospedeira, composição, uso de uma variante, e, método para tratar de um mamìfero tendo uma doença ou um distúrbio em que a formação de coágulo seja desejável BRPI0411650A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47978003P 2003-06-19 2003-06-19
DKPA200400930 2004-06-15
PCT/DK2004/000428 WO2004111242A1 (en) 2003-06-19 2004-06-18 FACTOR VII OR VIIa GLA DOMAIN VARIANTS

Publications (1)

Publication Number Publication Date
BRPI0411650A true BRPI0411650A (pt) 2006-08-08

Family

ID=33553697

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411650-0A BRPI0411650A (pt) 2003-06-19 2004-06-18 variante polipeptìdica do fator vii (fvii) ou do fator viia (fviia), sequencia de nucleotìdeos , vetor de expressão, célula hospedeira, composição, uso de uma variante, e, método para tratar de um mamìfero tendo uma doença ou um distúrbio em que a formação de coágulo seja desejável

Country Status (23)

Country Link
US (5) US20050164932A1 (cg-RX-API-DMAC7.html)
EP (1) EP1644504B8 (cg-RX-API-DMAC7.html)
JP (2) JP4915918B2 (cg-RX-API-DMAC7.html)
KR (1) KR101191779B1 (cg-RX-API-DMAC7.html)
CN (1) CN1839203B (cg-RX-API-DMAC7.html)
AT (1) ATE458057T1 (cg-RX-API-DMAC7.html)
AU (2) AU2004247799B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0411650A (cg-RX-API-DMAC7.html)
CA (1) CA2529828C (cg-RX-API-DMAC7.html)
CY (1) CY1109984T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004025576D1 (cg-RX-API-DMAC7.html)
DK (1) DK1644504T3 (cg-RX-API-DMAC7.html)
ES (1) ES2338425T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20100264T1 (cg-RX-API-DMAC7.html)
IL (1) IL172364A (cg-RX-API-DMAC7.html)
MX (1) MXPA05013769A (cg-RX-API-DMAC7.html)
NZ (2) NZ544728A (cg-RX-API-DMAC7.html)
PL (1) PL1644504T3 (cg-RX-API-DMAC7.html)
PT (1) PT1644504E (cg-RX-API-DMAC7.html)
RU (1) RU2373282C2 (cg-RX-API-DMAC7.html)
SI (1) SI1644504T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004111242A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200600539B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2319541A1 (en) 2000-02-11 2011-05-11 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
BR0309576A (pt) * 2002-04-30 2005-02-09 Maxygen Holdings Ltd Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
ES2386010T3 (es) * 2003-03-20 2012-08-07 Bayer Healthcare Llc Variantes de FVII o FVIIa
KR101191779B1 (ko) 2003-06-19 2013-01-14 맥시겐 홀딩스 엘티디 인자 ⅶ 또는 ⅶ에이 지엘에이 도메인 변종들
JP2008509688A (ja) 2004-08-17 2008-04-03 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 改変ビタミンｋ依存性ポリペプチド
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
EP1893632B1 (en) 2005-06-17 2015-08-12 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered factor vii proteins comprising at least one non-native cysteine
JP5147692B2 (ja) 2005-07-13 2013-02-20 ノボ ノルディスク ヘルス ケア アーゲー 治療用タンパク質生成のための宿主細胞タンパク質ノックアウト細胞
PL1907540T3 (pl) * 2005-07-22 2013-05-31 Bayer Healthcare Llc Aktywacja czynnika VII w roztworze
ES2515915T3 (es) 2005-09-01 2014-10-30 Novo Nordisk Health Care Ag Purificación de los polipéptidos del Factor VII mediante cromatografía de interacción hidrofóbica
JP5690047B2 (ja) 2005-09-14 2015-03-25 ノボ ノルディスク ヘルス ケア アーゲー ヒト凝固第ｖｉｉ因子ポリペプチド
EP2423305A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
ES2531934T3 (es) 2006-09-01 2015-03-20 Novo Nordisk Health Care Ag Glicoproteínas modificadas
FR2910969B1 (fr) * 2006-12-29 2009-02-27 Lab Francais Du Fractionnement Procede de mesure de la concentration de facteur viia (fviia) dans un echantillon
EP1952822A1 (en) * 2007-01-26 2008-08-06 Novo Nordisk A/S Factor VII polypeptides with increased affinity to platelets
NZ593611A (en) 2007-04-13 2012-06-29 Catalyst Biosciences Inc Modified factor vii polypeptides and uses thereof
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
WO2010149172A2 (en) 2009-06-24 2010-12-29 Rigshospitalet SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH.
FR2947181B1 (fr) * 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
DK3165232T3 (da) * 2012-12-24 2019-09-16 Coagulant Therapeutics Corp Faktor vii-polypeptider med kortvarig virkning
JP6595977B2 (ja) * 2013-03-15 2019-10-23 グラディエーター・バイオサイエンシーズ・インコーポレイテッド 治療剤としてのＧｌａドメイン
CN104211802B (zh) * 2013-05-29 2018-07-27 成都渊源生物科技有限公司 人凝血因子轻链蛋白及其应用
ES2943359T3 (es) 2014-12-10 2023-06-12 Opko Biologics Ltd Métodos de producción de polipéptidos de hormona de crecimiento modificados con CTP de acción prolongada
JP2019515904A (ja) * 2016-04-14 2019-06-13 アイコニック セラピューティクス，インコーポレイテッド 新血管新生に関連する障害を治療するための組成物および方法
US11976106B2 (en) 2016-07-11 2024-05-07 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
AU2018330427A1 (en) 2017-09-05 2020-04-02 GLAdiator Biosciences, Inc. Method of targeting exosomes
CN114728044A (zh) 2019-08-15 2022-07-08 介控生化科技公司 用于皮下施用和按需求治疗的经修饰的因子vii多肽

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA862768B (en) * 1985-04-17 1986-12-30 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5180583A (en) * 1985-11-26 1993-01-19 Hedner Ulla K E Method for the treatment of bleeding disorders
US5258288A (en) * 1986-07-25 1993-11-02 Genzyme Corporation Vector containing DNA encoding mature human protein S
DK323587D0 (da) 1987-06-25 1987-06-25 Novo Industri As Protein
JP2799316B2 (ja) 1987-06-12 1998-09-17 ヘキスト・マリオン・ルセル株式会社 雑種ヒトプロテインｃおよびその遺伝子工学的製法
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5648254A (en) * 1988-01-15 1997-07-15 Zymogenetics, Inc. Co-expression in eukaryotic cells
JPH0246296A (ja) 1988-08-09 1990-02-15 Hoechst Japan Ltd 雑種プロテインｃ及びその製造方法
US5218092A (en) 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
DE69101634T4 (de) 1990-01-26 1994-12-01 Immuno Ag Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
WO1991011514A1 (en) 1990-01-29 1991-08-08 Zymogenetics, Inc. Anticoagulant proteins
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5531916A (en) * 1990-10-03 1996-07-02 E. I. Du Pont De Nemours And Company Hydrofluorocarbon cleaning compositions
EP0574402B2 (en) * 1990-11-26 2012-08-01 Genetics Institute, LLC Expression of pace in host cells and methods of use thereof
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) * 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
DE69233398D1 (de) 1991-02-28 2004-09-16 Novo Nordisk As Modifizierter faktor-vii
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
JPH0720127A (ja) * 1993-05-07 1995-01-24 Eisai Co Ltd 各種ｐｉｖｋａの測定方法および測定試薬
ES2169074T3 (es) 1993-05-21 2002-07-01 Novo Nordisk Healthcare Ag Factor vii modificado para inhibir la reestenosis vascular o el deposito de plaquetas.
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
US5837843A (en) * 1996-11-08 1998-11-17 Oklahoma Medical Research Foundation Modified protein C
DE69735597T2 (de) * 1996-11-08 2006-12-21 Oklahoma Medical Research Foundation, Oklahoma Verwendung eines modifizierten protein-c
JP2001508783A (ja) 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
AU740207B2 (en) 1997-02-06 2001-11-01 Novozymes A/S Polypeptide-polymer conjugates having added and/or removed attachment groups
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6608183B1 (en) 1997-07-14 2003-08-19 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
AU8101698A (en) 1997-07-18 1999-02-10 Novo Nordisk A/S Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
US7247708B2 (en) * 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) * 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
ES2289824T3 (es) 1998-10-30 2008-02-01 Novozymes A/S Proteinas glicosiladas con alergenicidad reducida.
DE69938435D1 (de) 1998-10-30 2008-05-08 Novozymes As Niedrigallergene Proteinvarianten
AU1262900A (en) 1998-11-06 2000-05-29 Novo Nordisk A/S Method for the production of fvii
AU3629800A (en) 1999-03-16 2000-10-04 Children's Hospital Of Philadelphia, The Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
EP2319541A1 (en) * 2000-02-11 2011-05-11 Bayer HealthCare LLC Factor VII or VIIA-like conjugates
US7220837B1 (en) * 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
DE60143292D1 (de) 2000-05-03 2010-12-02 Novo Nordisk Healthcare Ag Varianten des menschlichen Koagulationsfaktors VII
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US7160540B2 (en) * 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
EP2226385B1 (en) 2000-09-13 2013-07-10 Novo Nordisk Health Care AG Human Coagulation Factor VII Variants
KR100882482B1 (ko) * 2000-09-13 2009-02-06 노보 노르디스크 헬스 케어 악티엔게젤샤프트 사람 응고 인자 ｖｉｉ 변이체
CA2422214A1 (en) * 2000-10-02 2002-04-11 Novo Nordisk A/S Factor vii glycoforms
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
AU2002249096B2 (en) 2001-03-22 2007-06-28 Novo Nordisk Health Care Ag Coagulation factor VII derivatives
PL368619A1 (en) 2001-09-27 2005-04-04 Novo Nordisk Health Care Ag Human coagulation factor vii polypeptides
JP2005512524A (ja) 2001-11-02 2005-05-12 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
CA2470511C (en) 2001-12-21 2014-05-27 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
BR0309576A (pt) * 2002-04-30 2005-02-09 Maxygen Holdings Ltd Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
CA2502162C (en) * 2002-09-30 2014-04-15 Maxygen Holdings Ltd. Fvii or fviia variants having increased clotting activity
ES2386010T3 (es) * 2003-03-20 2012-08-07 Bayer Healthcare Llc Variantes de FVII o FVIIa
US20060116324A1 (en) * 2003-06-13 2006-06-01 Novo Nordisk Healthcare A/G Novel formulations
KR101191779B1 (ko) * 2003-06-19 2013-01-14 맥시겐 홀딩스 엘티디 인자 ⅶ 또는 ⅶ에이 지엘에이 도메인 변종들

Also Published As

Publication number Publication date
AU2010200793A1 (en) 2010-03-25
CA2529828A1 (en) 2004-12-23
RU2373282C2 (ru) 2009-11-20
AU2010200793B2 (en) 2013-04-04
US20050164932A1 (en) 2005-07-28
SI1644504T1 (sl) 2010-06-30
US8987202B2 (en) 2015-03-24
JP4915918B2 (ja) 2012-04-11
US7807638B2 (en) 2010-10-05
AU2004247799A1 (en) 2004-12-23
NZ544728A (en) 2009-04-30
CY1109984T1 (el) 2014-09-10
HK1095357A1 (en) 2007-05-04
CA2529828C (en) 2013-01-15
IL172364A (en) 2014-01-30
US20070117756A1 (en) 2007-05-24
JP2012105650A (ja) 2012-06-07
US20060241041A1 (en) 2006-10-26
DE602004025576D1 (de) 2010-04-01
DK1644504T3 (da) 2010-05-25
CN1839203B (zh) 2011-11-16
KR101191779B1 (ko) 2013-01-14
US20060240526A1 (en) 2006-10-26
US20060252128A1 (en) 2006-11-09
CN1839203A (zh) 2006-09-27
NZ573412A (en) 2010-09-30
PL1644504T3 (pl) 2010-08-31
RU2006101391A (ru) 2006-06-10
EP1644504B1 (en) 2010-02-17
EP1644504B8 (en) 2010-06-02
ZA200600539B (en) 2006-12-27
HRP20100264T1 (hr) 2010-08-31
ES2338425T3 (es) 2010-05-07
MXPA05013769A (es) 2006-03-08
ATE458057T1 (de) 2010-03-15
AU2004247799B2 (en) 2009-12-03
JP2006527982A (ja) 2006-12-14
PT1644504E (pt) 2010-03-22
KR20060022283A (ko) 2006-03-09
JP5580283B2 (ja) 2014-08-27
WO2004111242A1 (en) 2004-12-23
EP1644504A1 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
BRPI0411650A (pt) variante polipeptìdica do fator vii (fvii) ou do fator viia (fviia), sequencia de nucleotìdeos , vetor de expressão, célula hospedeira, composição, uso de uma variante, e, método para tratar de um mamìfero tendo uma doença ou um distúrbio em que a formação de coágulo seja desejável
BR0309576A (pt) Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
Konttinen et al. Increased expression of extracellular matrix metalloproteinase inducer in rheumatoid synovium
BR0114475A (pt) Célula para a produção de composição de anticorpo
BR0113928A (pt) Polipeptìdio com uma sequência de aminoácidos, ácido nucléico, vetor, célula hospedeira, processo para a produção de polipeptìdeo e composição farmacêutica que contém uma quantidade farmaceuticamente efetiva do polipeptìdio
BR0008758A (pt) Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
CY1108689T1 (el) Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα
DE60322188D1 (de) Zytokin (zcytor17-ligand)
BR0317896A (pt) Complexos de cristais de proteìna e polìmeros iÈnicos
BR9814276A (pt) Antìgenos de superfìcie
BRPI0516176A (pt) polipeptìdeo, dna, microorganismo, e, processo para produzir l-arginina, l-ornitina ou l-citrulina
BR0211118A (pt) Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
PL1820509T3 (pl) Preparat leczniczy FVIIa o bardzo wysokiej czystości i sposób jego otrzymywania
WO2003035679A3 (en) Molecules
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
FR2861731B1 (fr) Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
BRPI0409736A (pt) anticorpos monoclonais, variantes de polipeptìdeo stop-1, molécula de ácido nucléico, vetor, célula hospedeira, composições, métodos relativos e artigos industrializados
WO2006114105A8 (en) Use of modified factor vii for treating bleeding
BR9912519A (pt) Variantes estabilizadas de inibidor de subtilisina de streptomyces
AU2001289034A1 (en) Novel pdes and uses thereof
ATE520025T1 (de) Test für morbus-parkinson-therapeutika
BR9804769A (pt) Processo para tratar ou prevenir infecção por pestivìrus em um hospedeiro mamìfero tendo ou sendo suscetìvel a referida infecção,e , para tratar c~elulas de mamìferos em cultura, e, em mamìferos biológicos
Kurtović et al. Ammodytagin, a heterodimeric metalloproteinase from Vipera ammodytes ammodytes venom with strong hemorrhagic activity
WO2002044737A3 (en) Diagnostic and therapeutic compositions and methods related to anaphylatoxin c3a receptor
BR9914466A (pt) "contortrostatina (cn) e métodos para seu uso na prevenção da metástase e outras condições"

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.